A phase 2 randomised discontinuation trial of cabozantinib in patients with ovarian carcinoma

Keyphrases

• Ovarian Carcinoma 100%
• Cabozantinib 100%
• Randomized Discontinuation Trial 100%
• Stable Disease 50%
• Objective Response Rate 50%
• Complete Response 33%
• Partial Response 33%
• Progression-free Survival 33%
• Placebo 16%
• Hypertension 16%
• Adverse Events 16%
• Tumor Subtype 16%
• Diarrhea 16%
• Clinical Activity 16%
• Neutropenia 16%
• Dose Reduction 16%
• Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) 16%
• Response Evaluation Criteria in Solid Tumors (RECIST) 16%
• Orally Bioavailable 16%
• Random Assignment 16%
• XL184 16%
• Asthenia 16%
• Tumor Regression 16%
• Target Lesion 16%
• Disease Control Rate 16%
• Palmar-plantar Erythrodysesthesia 16%
• Tumor Targeting 16%
• Platinum-refractory 16%
• Median Progression-free Survival 16%

Medicine and Dentistry

• Krukenberg Tumor 100%
• Cabozantinib 100%
• Diseases 57%
• Progression Free Survival 42%
• Tumor 28%
• Placebo 14%
• Neutropenia 14%
• Diarrhea 14%
• Drug Dose Reduction 14%
• Response Evaluation Criteria in Solid Tumors 14%
• Vasculotropin Receptor 2 14%
• Hand Foot Syndrome 14%
• Target Lesion 14%
• Asthenia 14%
• Tumor Regression 14%
• Hypertension 14%
• Platinum 14%
• Adverse Event 14%